This online, OnDemand educational activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty, and others in the planning and control of continuing medical education (CME) activities to disclose all their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.
Statement on off-label and investigational use: Faculty are asked to make a reasonable effort to identify during their presentation any discussion of off-label or investigative use or application of a product or device. Financial disclosures will appear at the beginning of each session and are provided below.
Faculty Disclosures
Scott Biggins, MD, MAS, FAASLD Grants/Research Support: Novartis Research
Peter Chin-Hong, MD Grants/Research Support: Karius
Janice Jou, MD, MHS, FAASLD Nothing to disclose.
Binita Kamath, MBBChir Scientific Consulting: Albireo, Mirum, Audentes (Astellas)
Laura Kulik, MD Speakers Bureau: Gilead Scientific Consulting: Eisai, Exelixis, Genetech
Jennifer Lai, MD, MBA Grants/Research Support: Vir Biotechnology, Axcella Health, Inc., Lipocine, Gore Medical
Josh Levitsky, MD, MS, FAASLD, FAST Grants/Research Support: Novartis Scientific Consulting: Mallinkrodt
Joseph Lim, MD, FAASLD Grants/Research Support: TARGET PharmaSolutions, Viking, Eiger; Leadership in related society: American College of Gastroenterology - Practice Parameters
Committee
Jessica Mellinger, MD Grants/Research Support: Salix Pharmaceuticals
Willscott Naugler, MD, FAASLD Nothing to disclose.
Jody Olson, MD Scientific Consulting: Mallinckrodt pharmaceuticals single time advisory board. Not an ongoing relationship
Mary Rinella, MD, FAASLD Nothing to disclose.
Mark Russo, MD, MPH, FAASLD Data Safety Monitoring Board for Industry or Commercial Enterprises: Moderna
Monika Sarkar, MD, MAS Grants/Research Support: I am the site PI for a clinical trial of an agent to treat NAFLD in women with polycystic ovary syndrome, sponsored by Zydus Pharmaceuticals. Funds received are solely used for research support.
Amit Singal, MD, MS, FAASLD Scientific Consulting: Bayer Pharmaceuticals, Eisai, Exelixis, FujiFilm/Wako Diagnostics
Debra Sudan, MD Nothing to disclose.
Shareef Syed, MBChB Nothing to disclose.
Ryan Taylor, MD, FAASLD Consulting for Equity (e.g. Venture Capital Firms): Abbive, Inc. Speakers Bureau: Gilead Sciences, Inc.
Amy Taylor, MD Nothing to disclose.
Gregory Tiao, MD Nothing to disclose.
Pamela L. Valentino, MD Nothing to disclose.
Elizabeth Verna, MD, MS Grants/Research Support: Salix Pharmaceuticals
Planner Disclosures
AASLD Maintenance of Certification Committee
Yumi Ando, MD Nothing to disclose.
Virginia C. Clark, MD, MS Grants/Research Support: Arrowhead Pharma, Genfit
Adam C. Deising, DO Nothing to disclose.
Nicole Gray, CNP Nothing to disclose.
Dina Halegoua-De Marzio, MD Scientific Consulting: Intercept
Adam James Hanje, MD, FAASLD Commercial Speaker's Bureau: Intercept, Salix
Janice Jou, MD, MHS, FAASLD Nothing to disclose.
Mitchell A. Mah'moud, MD, FACG, AGAF, FAASLD Scientific Consulting: Chronic Liver Disease Foundation
Ayse Leyla Mindikoglu, MD, MPH, FAASLD Nothing to disclose.
Kim Olthoff, MD Nothing to disclose
Yuval Patel, MD Scientific Consulting: Intercept
Stacey Prenner, MD Nothing to disclose.
Ryan Taylor, MD, FAASLD Consulting for Equity (e.g. Venture Capital Firms): Abbive, Inc. Speakers Bureau: Gilead Sciences, Inc.
Manish Thapar, MD, FAASLD Commercial Speaker's Bureau: Alnylum Pharmaceuticals
AASLD Governing Board
Carla Brady, MD, MHS, FAASLD Nothing to disclose
Raymond Chung, MD, FAASLD Grant/Research Support: Abbvie, Merck, Boehringer Ingelheim, Gilead, Janssen, BMS, Roche, Synlogic, Kaleido Other: Non-consulting General payment $250, Janssen; Asssociated Research PI payments to institution
Laurie DeLeve, MD, PhD, FAASLD – President Consulting: Daiichi-Sankyo Intellectual Property Rights: Compositions and Methods for Ameliorating Tissue Injury,Enhancing Liver Regeneration and Stem Cell Therapies (sole inventor)(GBC ref.: 6177.132445PCT);2017-230-01 US no. 62/544,589 End-organ selective MMP inhibition enhances bone marrow progenitor cell recruitment
Saul Karpen, MD, PhD, FAASLD Leadership in related society: Co-Chair of recently-formed International Liver Forum for Pediatric Cholestasis Scientific Consulting: Intercept Pharmaceuticals, Vertex, Albireo*, Mirum
W. Ray Kim, MD, FAASLD Consulting: Gilead Stock Options: Durect Grants/Research Support: Gilead, Roche, Genentech
Paul Martin, MD, FAASLD Consulting: ABIM, Up to Date, IQVIA
Kim Olthoff, MD Nothing to disclose
Vijay Shah, MD, FAASLD Intellectual Property Rights: US Patent - NOVEL BRD4 INHIBITORS TO TREAT LIVER DISEASE Consulting: Ambys Medicine, Durect Corporation, Novartis Pharma, AgomAb Therapeutics, Akaza Bioscience Ltd., Generon Shanghai, HepaRegeniX, Intercept Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Surrozen
Grace Su, MD, FAASLD Stock/Stock Options: Spouse- Equity interest in Applied Morphomics, Prenovo Leadership in related society: Member, Clinical Guidelines Committee, AGA
Mary Rinella, MD, FAASLD Consulting: Squibb & Sons, Intercept, Novo Nordisk,Siemens Medical, Amgen, Pfizer, Intercept
Norah Terrault, MD, MPH, FAASLD President-elect Consulting: Asssociated Research PI, CCO Hepatitis, CLDF, Simply Speaking, Gilead Sciences Data Safety Monitoring Board for industry or Commercial Enterprise: Moderna Grants/Research Support: Sciences, GSK, Roche-Genentech, Helio Health, Durect Corp
AASLD Staff Disclosures
Julie Deal Nothing to disclose
Matthew D’Uva Nothing to disclose
Lisa Patterson Nothing to disclose
Colin Syphax Nothing to disclose